Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01915498
Title	Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Celgene
Indications	acute myeloid leukemia myelodysplastic syndrome
Therapies	Enasidenib
Age Groups:	senior \| adult
Covered Countries	USA \| FRA